News

Automation, continuous manufacturing drive global pharmaceutical equipment demand

It is also driven by chronic diseases and biologics production.
2 days ago

Tam Anh invests $77m in proton therapy system

Deal signed during Vietnam-U.S. Comprehensive Strategic Partnership visit.
3 days ago

Aging population drives demand for durable medical equipment market

Telehealth, 3D printing, and customisation are amongst the key trends.
3 days ago

Hong Kong outlines ‘One plus Three’ model for life and health tech R&D

A headquarters for the Life and Health Technology Research Institutes will be set up.
4 days ago

Rising demand for advanced surgical devices to push market to $27.4b by 2032

Robotic-assisted surgery drives precision in complex procedures.
4 days ago

iX Biopharma secures $52.8m US contract for pain reliever trials

The funding will be allocated for the late-stage development of Wafermine. 
4 days ago

$85M funding to to boost health research, mRNA innovation in Australia

It targets serious health conditions with limited treatment options.
4 days ago

SLE, lupus nephritis market to more than double by 2034

It will be driven by nine new pipeline therapies targeting disease modification
4 days ago

NSAIDs and opioids dominate global pain therapeutics market

Regulatory incentives and innovative trial designs also boost market interest.
5 days ago

Fuel cell market projected to soar to $37.22b by 2034 on 14.8% CAGR

PEM fuel cells account for over 59% share.
5 days ago

Software, precision devices drive Australia’s diagnostic imaging growth

Australia held 4% of the APAC diagnostic imaging market in 2025.
5 days ago

Automation push to fuel 8.5% CAGR in pharma robot market through 2034

The market is estimated to ve valued at $226.24m in 2025.
6 days ago

DBS’ $72m loan to PLife REIT to finance elder care in Japan

The loan follows the REIT’s Sustainable Finance Framework.
6 days ago

Agentic AI cuts drug development timelines: report

Healthcare GenAI market seen growing to $22b by 2027.
6 days ago

Biopharma firms face $275b patent cliff as returns stall

BCG says pricing pressure, tariffs, and MFN policies are reshaping business models.
6 days ago